Decentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Decentralised or 'redistributed' manufacturing represents an attractive choice for production of some cell and gene therapies (CGTs), in particular personalised therapies. Decentralised manufacturing splits production into various locations or regions and in doing so, imposes organisational changes on the structure of a company. This confers a significant advantage by democratising supply, creating jobs without geographical restriction to the central hub and allowing a more flexible response to external pressures and demands. This comes with challenges that need to be addressed including, a reduction in oversight, decision making and control by central management which can be critical in maintaining quality in healthcare product manufacturing. The unwitting adoption of poor business strategies at an early stage in development has the potential to undermine the market success of otherwise promising products. To maximise the probability of realising the benefits that decentralised manufacturing of CGTs has to offer, it is important to examine alternative operational paradigms to learn from their successes and to avoid their failures. Whilst no other situation is quite the same as CGTs, some illustrative examples of established manufacturing paradigms are described. Each of these shares a unique attribute with CGTs which aids understanding of how decentralised manufacturing might be implemented for CGTs in a similar manner. In this paper we present a collection of paradigms that can be drawn on in formulating a roadmap to success for decentralised production of CGTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Huang, R., Riddle, M., Graziano, D., Warren, J., Das, S., Nimbalkar, S., Cresko, J., & Masanet, E. (2016) · Journal of Cleaner Production · doi:10.1016/j.jclepro.2015.04.109 · Cited by 805
Harrison, R. P., Ruck, S., Medcalf, N., & Rafiq, Q. A. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.07.005 · Cited by 72
Self-citation
Cited by
Therapeutic cancer vaccines: Advancements, challenges, and prospects
Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597
Identification of neoantigens for individualized therapeutic cancer vaccines
Lang, F., Schrörs, B., Löwer, M., Türeci, Ö., & Sahin, U. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00387-y · Cited by 534
Promises and challenges of adoptive T-cell therapies for solid tumours
Morotti, M., Albukhari, A., Alsaadi, A., Artibani, M., Brenton, J. D., Curbishley, S. M., Dong, T., Dustin, M. L., Hu, Z., McGranahan, N., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01353-6 · Cited by 269
Harrison, R. P., Rafiq, Q. A., & Medcalf, N. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.05.003 · Cited by 40
Self-citationGupta, D., & Shaz, B. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06400-x · Cited by 32
Metadata
- Authors
- Harrison, R. P., Ruck, S., Rafiq, Q. A., & Medcalf, N.
- Venue
- Biotechnology Advances
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 36
- Issue
- 2
- Pages
- 345-357
- ISSN
- 0734-9750 (ISSN-L)
- OpenAlex
- W2781105157
- Cited by
- 70
- References
- 2
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Decentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors. https://app.cochat.ai/papers/10.1016/j.biotechadv.2017.12.013
- The paper
- Harrison, R. P., Ruck, S., Rafiq, Q. A., & Medcalf, N. (2018). Decentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors. Biotechnology Advances. https://doi.org/10.1016/j.biotechadv.2017.12.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.